HilleVax, Inc. (NASDAQ:HLVX) Receives $9.20 Average PT from Analysts

HilleVax, Inc. (NASDAQ:HLVX - Get Free Report) has received a consensus recommendation of "Hold" from the six research firms that are currently covering the stock, MarketBeat reports. Six analysts have rated the stock with a hold rating. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $9.20.

HLVX has been the topic of a number of recent research reports. HC Wainwright restated a "neutral" rating and set a $2.00 price objective on shares of HilleVax in a research note on Monday, August 12th. JPMorgan Chase & Co. reaffirmed a "neutral" rating and issued a $5.00 price target (down previously from $24.00) on shares of HilleVax in a research note on Monday, July 8th. Stifel Nicolaus downgraded shares of HilleVax from a "buy" rating to a "hold" rating and reduced their price objective for the stock from $34.00 to $3.00 in a research note on Tuesday, July 9th. Leerink Partnrs lowered shares of HilleVax from a "strong-buy" rating to a "hold" rating in a report on Tuesday, July 9th. Finally, Leerink Partners downgraded shares of HilleVax from an "outperform" rating to a "market perform" rating and cut their price target for the stock from $28.00 to $2.00 in a report on Tuesday, July 9th.

HilleVax Stock Up 0.5 %

Shares of HilleVax stock traded up $0.01 during trading on Friday, reaching $1.88. The company's stock had a trading volume of 184,767 shares, compared to its average volume of 464,086. The business's 50-day moving average price is $1.81 and its 200-day moving average price is $7.50. HilleVax has a 52 week low of $1.55 and a 52 week high of $20.22. The firm has a market cap of $93.48 million, a PE ratio of -0.57 and a beta of 0.80.

HilleVax (NASDAQ:HLVX - Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.73) by ($0.10). Equities analysts predict that HilleVax will post -2.47 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. EntryPoint Capital LLC bought a new position in shares of HilleVax in the 1st quarter valued at $80,000. Tidal Investments LLC bought a new position in HilleVax in the first quarter valued at about $207,000. Maven Securities LTD acquired a new stake in shares of HilleVax during the second quarter valued at about $217,000. Algert Global LLC bought a new stake in shares of HilleVax during the second quarter worth about $519,000. Finally, Rhumbline Advisers increased its stake in shares of HilleVax by 27.0% in the second quarter. Rhumbline Advisers now owns 42,658 shares of the company's stock valued at $617,000 after buying an additional 9,073 shares during the period. Institutional investors own 86.42% of the company's stock.

About HilleVax

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.